Viridian Therapeutics Announces Board and Officer Changes
Ticker: VRDN · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1590750
Sentiment: neutral
Topics: governance, management-change
Related Tickers: VRDN
TL;DR
Viridian Therapeutics (VRDN) filed an 8-K detailing board and officer changes effective Jan 7, 2025.
AI Summary
Viridian Therapeutics, Inc. announced on January 7, 2025, a change in its board of directors. Specifically, the company reported the departure of certain officers and the election of new directors, along with updates to compensatory arrangements for its officers. The filing details these changes without specifying individual names or financial figures.
Why It Matters
Changes in a company's board and officer structure can signal shifts in strategy, governance, or operational focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and officer changes can indicate internal shifts that may affect company direction and stability.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- January 7, 2025 (date) — Effective date of changes
FAQ
What specific roles have changed within Viridian Therapeutics' officer and director positions?
The filing indicates a departure of certain officers and the election of new directors, but does not specify the exact roles affected.
Are there any new compensatory arrangements for officers mentioned in this filing?
Yes, the filing states there are updates to compensatory arrangements of certain officers.
When were these changes effective?
The earliest event reported, which includes these changes, was effective January 7, 2025.
Does this filing provide details on the reasons for the departure of officers or directors?
No, the filing reports the event of departure but does not provide specific reasons.
What is the primary purpose of this Form 8-K filing for Viridian Therapeutics?
The primary purpose is to report current information regarding the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
Filing Stats: 816 words · 3 min read · ~3 pages · Grade level 10.6 · Accepted 2025-01-10 16:05:20
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value VRDN The Nasdaq Stock Mar
- $480,000 — . Harmon's base salary was increased to $480,000 and his target discretionary bonus thre
- $1,662,000 — he grant date and a grant date value of $1,662,000 and (ii) a restricted stock unit award
- $554,000 — k unit award with a grant date value of $554,000, each granted pursuant to the Company's
Filing Documents
- d842633d8k.htm (8-K) — 26KB
- g842633g0110122025354.jpg (GRAPHIC) — 2KB
- 0001193125-25-004435.txt ( ) — 153KB
- vrdn-20250107.xsd (EX-101.SCH) — 3KB
- vrdn-20250107_lab.xml (EX-101.LAB) — 18KB
- vrdn-20250107_pre.xml (EX-101.PRE) — 11KB
- d842633d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viridian Therapeutics, Inc. Date: January 10, 2025 By: /s/ Stephen Mahoney Stephen Mahoney President, Chief Executive Officer